Publicaciones en colaboración con investigadores/as de University of British Columbia (12)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency

    Nature, Vol. 623, Núm. 7988, pp. 803-813

  3. Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia

    Journal of Experimental Medicine, Vol. 220, Núm. 5

  4. Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival from Sepsis

    Critical Care Explorations, Vol. 5, Núm. 11, pp. E0997

2022

  1. A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection

    Nature Immunology, Vol. 23, Núm. 2, pp. 159-164

2020

  1. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

    Science, Vol. 370, Núm. 6515

  2. Correction: Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritization (The Pharmacogenomics Journal, (2020), 20, 5, (621-628), 10.1038/s41397-019-0140-y)

    Pharmacogenomics Journal

  3. Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis

    American Journal of Respiratory and Critical Care Medicine, Vol. 201, Núm. 5, pp. 564-574

  4. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

    Science, Vol. 370, Núm. 6515

  5. Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation

    Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 621-628

2017

  1. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study

    The Lancet Respiratory Medicine, Vol. 5, Núm. 11, pp. 869-880

  2. Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium

    Pharmacogenomics, Vol. 18, Núm. 10, pp. 931-943